PharmaFocus Today – Page 16 – media

ACR Releases New Guideline for Lupus Treatment in Adults and Children

The American College of Rheumatology (ACR) has released a summary of a guideline with updated recommendations for the treatment of systemic lupus erythematosus (SLE). The previous guideline for managing SLE in adults was published in 1999, said Lisa R. Sammaritano, MD, of the Hospital for Special Surgery in New York City, who led the project. At that time, “the recommended management for severe disease was high-dose steroid (eg, prednisone) plus an immunosuppressive agent, usually azathioprine or cyclophosphamide,” she told Medscape Medical News. “Since then, the spectrum of available therapies for SLE treatment has broadened considerably, and there have been important changes in our understanding of optimal use of rheumatology therapies, both new and old.” This new guideline, applicable to both adults and children, focuses on reaching and maintaining remission or lower disease activity and minimizing treatment-related toxicities. The guideline summary was posted last month on the ACR website, and ...
- Source: drugdu
- 95
- June 9, 2025
Organic Ground Beef Sold at Whole Foods May Be Contaminated With E. Coli, USDA Says

THURSDAY, June 5, 2025 (HealthDay News) — Some packages of organic ground beef sold at Whole Foods stores across the country may be contaminated with E. coli, federal officials have warned. The U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) issued a public health alert Wednesday about one-pound packages of “ORGANIC RANCHER ORGANIC GROUND BEEF 85% LEAN 15% FAT.” The affected beef was produced May 22 and 23, 2025, and has “Use or Freeze By 06-19-25” or “Use or Freeze By 06-20-25” printed on the label. The packaging also includes the establishment number “EST. 4027” inside the USDA mark of inspection, CBS News reported. While this beef is no longer being sold in stores, officials say some may still be in customers’ homes. Anyone with this product should not eat it. “These products should be thrown away or returned to the place of purchase,” the alert stated. ...
- Source: drugdu
- 75
- June 9, 2025
Obtained medical device registration certificate for two new products suitable for renal treatment

Tianyi Medical announced on the evening of June 5 that the company recently received the ” Medical Device registration certificate involves two new products, namely a disposable continuous renal replacement therapy tube and a disposable hemodialysis tube. According to the announcement, the disposable continuous renal replacement therapy tubing consists of tubing, threaded pre-filled needles, etc., and is used as a blood and fluid channel during continuous renal replacement therapy (CRRT); the disposable hemodialysis tubing consists of arterial tubes, venous tubes, etc., and is used as a blood channel for hemodialysis and hemodiafiltration mode treatment of patients with acute and chronic renal failure. Both products are sterilized with ethylene oxide and are disposable products. According to information, Tianyi Medical is a high-tech enterprise mainly engaged in the research, development, production and sales of medical devices such as medical polymer consumables in the fields of blood purification and ward nursing. It is ...
- Source: drugdu
- 63
- June 9, 2025
Sino Biopharmaceutical Announces Breakthrough Results of Phase III Clinical Study on Non-Small Cell Lung Cancer at ASCO Annual Meeting

On June 5, China Biopharmaceuticals announced that the company announced the results of a Phase III clinical study on non-small cell lung cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study showed that the median progression-free survival (PFS) of the treatment group using bemosubishi combined with anlotinib was significantly extended to 15.1 months, while the control group was only 4.2 months, and the risk of disease progression or death was reduced by 51%. A total of 553 patients were included in this study, including 209 patients in trial group 1, 212 patients in trial group 2, and 132 patients in the control group. Preliminary results showed that the median PFS of trial group 1 was extended by 10.9 months compared with the control group, and trial group 2 was also significantly extended by 5.5 months. In terms of safety, the incidence of grade ≥3 treatment-related ...
- Source: drugdu
- 57
- June 9, 2025
Fuyuan Pharmaceutical’s Ketoprofen Patch Approved for Clinical Trial

On June 5, Fuyuan Pharmaceutical announced that it had recently received the “Drug Clinical Trial Approval Notice” for Ketoprofen Patch approved and issued by the State Drug Administration. The drug’s indications include a variety of pain and inflammation-related diseases, such as low back pain, osteoarthritis and rheumatoid arthritis. Ketoprofen patches have been approved in countries or regions such as Japan, Italy, and Portugal, but as of June 2025, no manufacturer has imported them for sale. According to data from MinEnet, the sales of ketoprofen patches in the Chinese market in 2024 will be about 5 million yuan, of which sales in urban public hospitals and county-level public hospitals will be 2.33 million yuan, and sales in urban physical pharmacies and online pharmacies will be 2.67 million yuan. The product still needs to go through the relevant approval procedures before it can be launched, and there is still uncertainty as to ...
- Source: drugdu
- 71
- June 9, 2025
The medical price and procurement credit evaluation system will be further improved to increase the punishment for dishonest behavior.

In order to guide enterprises to operate with integrity and compliance and further promote the healthy development of the centralized pharmaceutical procurement market, the National Healthcare Security Administration recently issued the “Notice on Further Improving the Pharmaceutical Price and Procurement Credit Evaluation System” to revise the pharmaceutical price and procurement credit evaluation system. In August 2020, the National Healthcare Security Administration issued the Guiding Opinions on Establishing a Credit Evaluation System for Pharmaceutical Prices and Procurement, and carried out credit rating, graded disposal, credit repair and other work based on the facts of cases such as drug sales with money and bid rigging determined by court judgments or administrative penalties. By the end of 2024, 735 untrustworthy enterprises were assessed, including 7 “particularly serious” untrustworthy enterprises, 40 “serious” untrustworthy enterprises, 76 “medium” untrustworthy enterprises, and 612 “general” untrustworthy enterprises. The implementation of this system has played a positive role in ...
- Source: drugdu
- 54
- June 9, 2025
Proinflammatory Foods Tied to Higher Risk of Death in Colon Cancer Patients

WEDNESDAY, June 4, 2025 (HealthDay News) — What you eat after a colon cancer diagnosis could do more than affect your energy or digestion — it might impact your chance of survival. Researchers looked at more than 1,600 patients with stage 3 colon cancer. They found that those who ate the most proinflammatory foods had an 87% higher risk of death compared to those who ate the least. These foods may cause an inflammatory response such swelling or irritation in the body. Over time, this type of chronic inflammation is linked to many diseases, including cancer, The Independent of London reported. “One of the most common questions that patients ask is what they should do after treatment to maximally reduce their risk of cancer recurrence and improve survival,” said lead author Dr. Sara Char, a clinical fellow at Dana-Farber Cancer Institute in Boston. “These findings add to the published literature ...
- Source: drugdu
- 81
- June 6, 2025
Wayne State researchers investigate effects of fentanyl use during pregnancy

A new National Institutes of Health (NIH) grant will aid Wayne State University researchers in measuring the effects of fentanyl during pregnancy on maternal behaviors and offspring at birth through early development. This two-year, $423,500 grant, “Understanding the effects of gestational fentanyl exposure on external morphology, neonatal opioid withdrawal, and brain volume, morphology and neurochemistry of offspring,” is supported by the National Institute on Drug Abuse of the NIH. The principal investigators on this study are Shane Perrine, Ph.D., associate professor of psychiatry and behavioral neurosciences in Wayne State’s School of Medicine, and Susanne Brummelte, Ph.D., professor of psychology in Wayne State’s College of Liberal Arts and Sciences. “Our labs have collaborated on prior studies and this project is a natural extension of our previous work. I was working on the study of illicit fentanyl use and Susie’s lab was looking at the effects of opioids, including morphine and buprenorphine, ...
- Source: drugdu
- 74
- June 6, 2025
The second new drug application for the combination of Xindilimumab and Fruquintinib has been accepted by the National Medical Products Administration

On June 5th, Xinda Biotechnology and Hehuang Pharmaceutical jointly announced that the new drug application for the combination therapy of Xindilimumab and Fruquintinib for the treatment of locally advanced or metastatic renal cell carcinoma patients who have previously failed treatment with a tyrosine kinase inhibitor has been accepted by the National Medical Products Administration (NMPA) of China. It is reported that the combination therapy of xindilimab and furosemide obtained conditional approval from NMPA in December 2024 for the treatment of advanced mismatch repair intact (pMMR) endometrial cancer patients who have failed previous systemic anti-tumor therapy and are not suitable for radical surgery or radiotherapy.
- Source: drugdu
- 87
- June 6, 2025
BCHT’s recombinant shingles vaccine clinical trial application approved

On the evening of June 4, BCHT, the company announced that it had received the “Notice of Approval for Drug Clinical Trial” for the recombinant herpes zoster vaccine (CHO cells) issued by the National Medical Products Administration, and the conclusion was that it agreed to conduct clinical trials for the prevention of herpes zoster. Herpes zoster is an acute infectious skin disease caused by the reactivation of the varicella-zoster virus (VZV) lurking in the body. The recombinant herpes zoster vaccine (CHO cells) approved for clinical use by Biotech is for adults aged 40 and above. After vaccination, it can stimulate the body to produce immunity against the varicella-zoster virus and is used to prevent herpes zoster. According to reports, the recombinant shingles vaccine (CHO cells) developed by the company is based on varicella-zoster virus glycoprotein E (gE protein) and is combined with the company’s independently developed innovative BK-02 adjuvant system. ...
- Source: drugdu
- 76
- June 6, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.